It is not clear how Escherichia coli O157 invades human enteric epithelium and causes the haemolytic uraemic syndrome (HUS), and nor has the most appropriate treatment of E. coli O157 infection been established. Verotoxins, leucocytes and proinflammatory cytokines, such as tumour necrosis factor-alpha (TNF-), interleukin (IL)-6 and IL-8, are considered essential for the development of HUS. We used the Caco-2 cell monolayer system, well-known as an invitro model of human intestinal infection, to determine how E. coli O157 interacts with intestinal epithelial cells and also studied the influence of fosfomycin on the virulence of the bacteria. Results showed that the E. coli O157 used in this study did not penetrate the Caco-2 cell monolayer system, unlike Salmonella typhimurium SL1344, and verotoxin 1 (VT 1), but not VT 2, translocated across the system. In an in-vitro conventional assay, fosfomycin increased the amount of verotoxins but it did not influence penetration of bacteria and translocation of verotoxins in the Caco-2 cell monolayer system. The production of both IL-8 (a potent neutrophil activator) and TNF-in the human monocytic THP-1 cell line was reduced by fosfomycin-treated basolateral medium in this system. These results indicate that fosfomycin may be a potent drug for preventing HUS caused by E. coli O157 infection.
Introduction
Very large outbreaks of Escherichia coli O157 infection occurred in Japan in 1996: by the end of 1996, approximately 10,000 cases had been reported and 12 patients had died. Sporadic cases had been reported in Japan before 1996; such outbreaks have never been reported elsewhere in the world. 1 The most serious complication of E. coli O157 infection is the haemolytic uraemic syndrome (HUS), which causes acute renal failure, microangiopathic haemolytic anaemia and thrombocytopenia. [2] [3] [4] [5] This complication is most common in children. 2, [6] [7] [8] Verotoxin is thought to damage human endothelial cells and lead to HUS. [9] [10] [11] [12] [13] [14] The degree of HUS is closely related to levels of proinflammatory cytokines, such as human tumour necrosis factor-alpha (TNF-) and interleukin 6 (IL-6), since they regulate endothelial cell membrane expression of glycolipid globotriaosylceramide (Gb 3 ), which serves as the verotoxin receptor. 15, 16 Neutrophil leucocytosis is also thought to damage human endothelial cells, 17, 18 so IL-8, another proinflammatory cytokine and a potent activator of neutrophils, also plays an important role in E. coli O157 infection. 19 The first step in infection is adherence and growth of E. coli O157 on the surface of the enteric epithelium. Almost all enterohaemorrhagic E. coli (EHEC), including E. coli O157, are thought to adhere to the membrane and develop 'attaching and effacing' lesions, but some strains invade certain cultured cell lines. 20, 21 Secondly, verotoxin is thought to pass from the intestinal tract lumen to underlying tissues. transepithelial electrical resistance as does human intestinal epithelium. [23] [24] [25] Since these characteristics resemble enterocytes of the fetal colon, the Caco-2 cell monolayer system is recognized as an in-vitro model of intestinal infection. 23 In the present study, we infected Caco-2 cells with E. coli O157 to examine whether they could penetrate the monolayers and translocate to the basolateral medium. 26 No antibiotics are specifically indicated at present for E. coli O157 infection. Some antibiotics have been reported to enhance the release of verotoxin in vitro, 27 and it is possible that antibiotics may aggravate the disease by releasing a large amount of verotoxin and proinflammatory cytokines induced by human monocytes. 28 In Japan in 1996, most physicians treated E. coli O157 infection with fosfomycin, which is widely used for paediatric dysentery in Japan. 29 More recently, it has been reported that fosfomycin also enhances the release of verotoxin in vitro, 30, 31 but it is not known how it does this in bacteria adhering to the colon membrane of patients infected with E. coli O157. We analysed the influence of fosfomycin on the release of verotoxin both in the Caco-2 cell monolayer system and in a conventional in-vitro system, and investigated penetration of E. coli O157 and translocation of verotoxin through the Caco-2 cell monolayer system. We also studied differences in production of proinflammatory cytokines by the human monocytic THP-1 cell line by components released from the bacteria in the presence and absence of fosfomycin.
Materials and methods

Bacterial strains
A clinical strain of E. coli O157 isolated in Nagasaki prefecture in August 1996, producing verotoxins 1 and 2 (VT 1 and 2), was used. The MIC of fosfomycin (Meiji Seika Kaisha Ltd, Tokyo, Japan) was determined by a microdilution method with cation-adjusted MuellerHinton broth (BBL Microbiology Systems, Cockeysville, MD, USA) according to the recommendations of the NCCLS 32 in the presence or absence of 25 mg/L of glucose 6-phosphate. MICs in the presence and absence of glucose 6-phosphate were 0.5 and 4 mg/L, respectively. Salmonella typhimurium SL1344 and E. coli DH5 were used as positive and negative controls, respectively, for the monolayer penetration assays (kindly provided by Dr B. Brett Finlay, Biotechnology Laboratory and Department of Microbiology and Biochemistry, University of British Columbia, Vancouver, Canada). Bacterial identification and verotoxin production were confirmed using Vitek Gram-Negative Identification Cards (bioMerieux-Vitek, Inc., Hazelwood, MO, USA) and a reversed passive latex agglutination test (RPLA; Denka Seiken Co., Ltd, Tokyo, Japan), respectively.
Verotoxin release in the in-vitro conventional assay
Freshly grown E. coli O157 were adjusted to a concentration of 1 10 7 cfu/mL in Mueller-Hinton broth. After 0, 3 or 7 h incubation with shaking at 37°C, fosfomycin (final concentrations 400 mg/L) was added to the broth followed by another 2 h shaking. Controls received no fosfomycin. The supernatants were then collected by centrifugation at 1500g for 15 min. VT 1 and VT 2 in the supernatants were measured by RPLA. Experiments were performed at least three times.
Caco-2 cells
Caco-2 cells were grown in Eagle's minimal essential medium (Nissui Pharmaceutical Co., Ltd, Tokyo, Japan) with nonessential amino acids and 10% fetal calf serum containing 1000 U/L penicillin G (Sigma Chemical Co., St Louis, MO, USA) and 100 mg/L streptomycin (Sigma). Transwell filter units (3415; Costar, Cambridge, MA, USA) with a 0.33 cm 2 porous filter membrane (3.0 m pores) were incubated in 24-well plates (Costar). Trypsinized Caco-2 cell suspension (150 L/well; 1.5 10 5 cells/well) in tissue culture medium was added apically to each Transwell unit. Both apical and basolateral media were changed every 3 days, and monolayers were used after 14 days of incubation at 37°C in 5% CO 2 .
Monolayer penetration assay and electrical resistance measurements
Monolayers were infected with bacteria by replacing the medium in the Transwell unit with 150 L of freshly grown bacterial suspension adjusted to 1 10 8 cfu/mL (10 7 cfu/well) with antibiotic-free medium to the apical chamber. To the lower chamber was also added 600 L of fresh antibiotic-free medium. S. typhimurium SL1344, E. coli DH5 and the clinical isolate of E. coli O157 were added to each apical surface of the polarized monolayers in quadruplicate and incubated at 37°C. The electrical resistance across the monolayer was measured after 1, 2, 4, 6, 8 and 12 h of incubation with a Millicell-ERS apparatus (Millipore Corporation, Bedford, MA, USA) according to Finlay & Falkow. 23 The area times the resistance (in cm 2 ) was calculated by multiplying the measured resistance by the area of the filter (0.33 cm 2 ). The basolateral medium was replaced with fresh medium at each time and bacteria in the removed medium were counted by plating appropriate dilutions on Mueller-Hinton agar (BBL).
Translocation of verotoxins across the Caco-2 cell monolayer
E. coli O157 (1 10 8 cfu/well) was added to Caco-2 cells and 3 h after bacterial inoculation, solution containing 0 or 400 mg/L of fosfomycin was added to the apical chamber. At 4, 5 and 7 h after bacterial inoculation, supernatants were collected from both the apical and lower chambers. The number of bacteria in the lower chamber was counted as previously described. The amount of verotoxin in both the apical and lower chambers was also measured by RPLA.
THP-1 cells
THP-1 cells were maintained in endotoxin-free RPMI 1640 (Gibco-BRL, Grand Island, NY, USA) supplemented with penicillin G (1000 U/L), streptomycin (100 mg/L) and endotoxin-guaranteed 10% fetal bovine serum (Gibco-BRL) at 37°C in 5% CO 2 
Cytokine assays
Supernatant was collected from untreated THP-1 cells and cells treated for 24 h with 50 L of basolateral medium, with or without fosfomycin added to the apical chamber in the Caco-2 cell monolayer system. A concentration of 5 ng/mL of E. coli O55:B5-derived lipopolysaccharide (LPS; Difco Laboratories, Detroit, MI, USA), with or without 400 mg/L of fosfomycin was used, a concentration of 5 ng/mL of purified VT 1 and VT 2 (Denka Seiken) were used as positive controls. Concentrations of human TNF-and IL-8 in the supernatant were determined by an enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Student's t-test was used to compare means; a P level of 5% was considered significant. Figure 1 shows the influence of fosfomycin on release of verotoxins. Fosfomycin enhanced the release of VT 1 even without pre-shaking the culture before addition of fosfomycin (P 0.0001). Release of VT 2 was also enhanced by fosfomycin after 3 h shaking incubation (P 0.0021). Figure 2 shows the number of bacteria that penetrated the Caco-2 cell monolayer and reduction of transepithelial electrical resistance. S. typhimurium SL1344 penetrated the Caco-2 cell monolayer 1 h after inoculation and transepithelial electrical resistance began to decrease at that time. E. coli DH5 penetrated the Caco-2 cell monolayer 6 h after inoculation and loss of transepithelial electrical resistance was not noticeable as reported by Finlay & Falkow. 23 E. coli O157 (10 7 cfu/well) did not penetrate the Caco-2 cell monolayer and loss of transepithelial electrical resistance was less than that with E. coli DH5 . E. coli O157 did not even penetrate when inoculated at 10 8 cfu/well (data not shown).
Results
Verotoxin release in in-vitro conventional assay
Monolayer penetration assay and loss of electrical resistance
Translocation of verotoxins across the Caco-2 cell monolayer
There were no E. coli O157 bacteria in the lower chamber at any time tested. Figure 3 shows the amount of VT 1 and VT 2 in both the apical and lower chambers. Only VT 1 translocated across the Caco-2 cell monolayer after 3 h of incubation, while VT 2 did not translocate within the study period. The influence of fosfomycin on the amount of VT 1 in the lower chamber was not significant. Figure 4 shows the production of both TNF-and IL-8 in the supernatant collected from untreated THP-1 cells or cells treated with 50 L of the basolateral medium (which contained or did not contain fosfomycin in the apical chamber) in the penetration assay for 24 h determined by ELISA. The THP-1 cells produced both TNF-and IL-8 when stimulated with 5.0 ng/mL of LPS in the presence or absence of fosfomycin, 5.0 ng/mL of purified VT 1 and VT 2. The supernatants of conventional assay which were treated with or without fosfomycin also induced the production of both cytokines (data not shown). Basolateral medium in the penetration assay in the presence of fosfomycin significantly reduced the production of both IL-8 (P 0.0002) and TNF-(P 0.0111).
Cytokine production
Discussion
The optimal treatment of E. coli O157 infection has not been established. The Japanese Ministry of Health and Welfare specified guidelines for treating E. coli O157 infection in 1996; fosfomycin, quinolones and kanamycin are recommended in the early stage of the infection. However, in-vitro studies suggested that these three types of antibacterial agent enhance the release of verotoxins, 30 which are considered essential for the development of HUS. If verotoxins are released from E. coli O157 in vivo in a similar way, administration of drugs to patients with E. coli O157 infection may make the disease much worse. Indeed, our results showed that high concentrations of fosfomycin enhanced the release of verotoxins, particularly VT 1, from E. coli O157 in the in-vitro conventional assay. However, it has not been confirmed whether fosfomycin also has this enhancement effect in vivo. Since the Caco-2 cell monolayer system is well known as a human intestinal infection model, we used it to examine the influence of fosfomycin on the penetration of bacteria, production and translocation of verotoxins.
The E. coli O157 tested in this study did not penetrate the monolayer when inoculated at 10 7 or 10 8 cfu/well in the apical chamber of the Caco-2 cell monolayer system. Fosfomycin did not influence penetration of bacteria when added to the apical chamber. We also used two endemic strains isolated in Sakai City, Osaka prefecture and Okucho, Okayama prefecture, Japan where large outbreaks of E. coli O157 infection occurred in 1996. Neither strain penetrated the Caco-2 cell monolayer system, either in the presence or absence of fosfomycin (data not shown).
On the other hand, VT 1, but not VT 2, translocated across the Caco-2 cell monolayer. Fosfomycin did not increase significantly the amounts of VT 1 and VT 2 in the apical chamber of this system, and also did not affect the amount of VT 1 translocated. These results suggest firstly that fosfomycin may have no influence on the release of verotoxins or on the amount of verotoxins passing from the human intestinal lumen to underlying tissue and also that the mechanisms of translocation of VT 1 and VT 2 across the human intestinal epithelial cells are different.
The antimicrobial activity of fosfomycin under anaerobic conditions is superior to that under aerobic conditions. 34 Our penetration experiment was performed under aerobic conditions, and the results might have been different if the experiments had been performed under anaerobic conditions. Moreover, the target cells for verotoxin action are vascular endothelial cells, and proinflammatory cytokines including TNF-, IL-1 and IL-6 play important roles in regulating the expression of the toxin receptor Gb 3 . 15, 16 Elevated plasma concentrations of TNF-, IL-6 and IL-8 have been reported in HUS patients, 15, 19, 35, 36 so we investigated whether the basolateral medium collected from the penetration assay could induce TNF-or IL-8 production in the human myelogenous leukaemia THP-1 cell line. All mature THP-1 cells produced large amounts of both TNF-and IL-8 when stimulated with a low concentration of purified VT 1, VT 2 and LPS with or without fosfomycin. The production of these two cytokines, especially IL-8, was reduced by fosfomycin in the Caco-2 cell monolayer system. Production of TNF-and IL-1 by LPS-primed human monocytes has been reported to be inhibited by fosfomycin. 37 Fosfomycin may also inhibit IL-8 production.
In conclusion, the E. coli O157 used in this study did not penetrate the Caco-2 cell monolayer system and only VT 1 translocated across Transwell units. Fosfomycin influenced neither the penetration of bacteria nor the translocation of verotoxins. The induction of proinflammatory cytokines, including TNFand IL-8, was inhibited by fosfomycin-treated samples. These data suggest that fosfomycin may be suitable for preventing HUS caused by E. coli O157 infection. 
